Alpha-synuclein, lipids and Parkinson's disease
- PMID: 20580911
- DOI: 10.1016/j.plipres.2010.05.004
Alpha-synuclein, lipids and Parkinson's disease
Abstract
Parkinson's disease is the second most common neurodegenerative disease, after Alzheimer's disease, among the aging human population. The main symptoms of Parkinson's disease such as tremor and movement disabilities are the result of degeneration of dopaminergic neurons in substantia nigra pars compacta. The widely-accepted subcellular factor which underlies Parkinson's disease neuropathology is the presence of Lewy bodies with characteristic inclusions of aggregated alpha-synuclein. This small soluble protein has been implicated in a range of interactions with phospholipid membranes and free fatty acids. The precise biological function of this protein is, however, still under investigation. Here we review the evidence linking alpha-synuclein, lipid metabolism, fatty acid oxidation, mitochondrial damage and Parkinson's disease. We propose that association of alpha-synuclein with oxidized lipid metabolites can lead to mitochondrial dysfunction in turn leading to dopaminergic neuron death and thus to Parkinson's disease.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
-
Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?Biomolecules. 2015 Jul 16;5(3):1467-79. doi: 10.3390/biom5031467. Biomolecules. 2015. PMID: 26193328 Free PMC article. Review.
-
Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease.Br J Pharmacol. 2022 Jan;179(1):23-45. doi: 10.1111/bph.15684. Epub 2021 Nov 24. Br J Pharmacol. 2022. PMID: 34528272 Review.
-
Determinants of dopaminergic neuron loss in Parkinson's disease.FEBS J. 2018 Oct;285(19):3657-3668. doi: 10.1111/febs.14607. Epub 2018 Aug 14. FEBS J. 2018. PMID: 30028088 Free PMC article. Review.
-
Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson's disease.J Neural Transm (Vienna). 2024 Jun;131(6):639-661. doi: 10.1007/s00702-023-02730-6. Epub 2024 Jan 9. J Neural Transm (Vienna). 2024. PMID: 38196001 Review.
Cited by
-
Potential Therapeutic Effects of Policosanol from Insect Wax on Caenorhabditis elegans Models of Parkinson's Disease.J Neuroimmune Pharmacol. 2023 Jun;18(1-2):127-144. doi: 10.1007/s11481-022-10057-4. Epub 2023 Jan 13. J Neuroimmune Pharmacol. 2023. PMID: 36637699
-
Gender specific decrease of a set of circulating N-acylphosphatidyl ethanolamines (NAPEs) in the plasma of Parkinson's disease patients.Metabolomics. 2019 May 3;15(5):74. doi: 10.1007/s11306-019-1536-z. Metabolomics. 2019. PMID: 31053995 Free PMC article.
-
Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease.Front Aging Neurosci. 2018 Jun 18;10:178. doi: 10.3389/fnagi.2018.00178. eCollection 2018. Front Aging Neurosci. 2018. PMID: 29967579 Free PMC article.
-
Intrinsic and membrane-facilitated α-synuclein oligomerization revealed by label-free detection through solid-state nanopores.Sci Rep. 2016 Feb 11;6:20776. doi: 10.1038/srep20776. Sci Rep. 2016. PMID: 26865505 Free PMC article.
-
Statistical segmentation model for accurate electrode positioning in Parkinson's deep brain stimulation based on clinical low-resolution image data and electrophysiology.PLoS One. 2024 Mar 14;19(3):e0298320. doi: 10.1371/journal.pone.0298320. eCollection 2024. PLoS One. 2024. PMID: 38483943 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous